This information was originally presented at the NCCN 20th Annual Conference: Advancing the Standard of Cancer Care™ held in Hollywood, Florida.

This information was originally presented at the NCCN 20th Annual Conference: Advancing the Standard of Cancer Care™ held in Hollywood, Florida.

This information was originally presented at the NCCN 20th Annual Conference: Advancing the Standard of Cancer Care™ held in Hollywood, Florida.

These NCCN Guidelines Insights focus on recent updates to the 2015 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC). Appropriate targeted therapy is very effective in patients with advanced NSCLC who have specific genetic alterations.

This symposium has been designed to bring up-to-date scientific information to clinicians involved in the care of patients with thoracic malignancies, including Lung Cancer, Mesothelioma, and Esophageal Cancer.

Hepatoid adenocarcinoma of the lung (HAL) is an extremely rare cancer without clear treatment guidance and with a poor prognosis.

Lung cancer is the leading cause of cancer death in the United States. Oncologists need to be aware of new treatment options and recommendations so they can implement the best treatment plans and thus improve outcomes for their patients with lung cancer.

Lung cancer is the leading cause of cancer death in the United States. Oncologists need to be aware of new treatment options and recommendations so they can implement the best treatment plans and thus improve outcomes for their patients with lung cancer.

Lung cancer is the leading cause of cancer death in the United States. Oncologists need to be aware of new treatment options and recommendations so they can implement the best treatment plans and thus improve outcomes for their patients with lung cancer.

Join Leora Horn, MD, MSc, FRCPC and Christine Lovly, MD, PhD as they present their multidisciplinary expertise on a range of cases pertaining to biomarker driven advanced disease lung cancer.